Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 211

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 211
---
 the application of significant resources to design, develop, test and maintain our products and services to help ensure that
AI is implemented in accordance with applicable law and regulation and in a socially responsible manner and to minimize any real or perceived
unintended harmful impacts. Our vendors may in turn incorporate AI tools into their own offerings, and the providers of these AI tools
may not meet existing or rapidly evolving regulatory or industry standards, including with respect to privacy and data security. Further,
bad actors around the world use increasingly sophisticated methods, including the use of AI, to engage in illegal activities involving
the theft and misuse of personal information, confidential information and intellectual property. Any of these effects could damage our
reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and adversely
impact our business.

The impact of recent healthcare reform legislation
and other changes in the healthcare industry and in healthcare spending on us is currently unknown, and may adversely affect our business
model.

Our revenue prospects could
be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry and
new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare
availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations
and financial condition.

There have been, and likely
will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability
of healthcare and containing or lowering the cost of healthcare. For more information, see the section of this report titled “Business
– Healthcare Laws and Regulations – Healthcare Reform.”

The continuing efforts of
the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of
healthcare and/or impose price controls may adversely affect:

●the demand for our product candidates, if we obtain regulatory approval;

●our ability to set a price that we believe is fair for our products;

●our ability to obtain coverage and reimbursement approval for a product;

●our ability to generate revenue and achieve or maintain profitability;

●the level of taxes that we are required to pay; and

●the availability of capital.

Any reduction in reimbursement
from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect
our future profitability.

Our business could be negatively impacted
by environmental, social and corporate governance matters or our reporting